Abstract
Objectives: In patients with advanced ovarian cancer, resection of all gross residual disease is associated with a significant improvement in survival. Disease remaining either as infiltrative or microscopic tumor deposits is a challenge to identify. Detection of this disease during cytoreductive surgery may lead to a more thorough reduction of cancer burden. We evaluated the performance of a fluorescent molecular imaging agent, LUM015 (Lumicell, Wellesley, MA), which is activated by cathepsin enzymes in the tumor, and a wide field-of-view imaging device (Lumicell) to detect sub-millimeter residual cancer clusters in an mouse model for ovarian cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
